Evidence map›Paper›PMID 41444043›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Is it time to think about chronotherapy in migraine.

Philip R Holland, Rolf Fronczek

Abstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The evolving landscape of primary headache therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Philip R HollandHeadache Group, Wolfson Sensory Pain and Regeneration Centre (WSPaRC), Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: philip.holland@kcl.ac.uk.
Rolf FronczekDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is among the most dynamic and disabling neurological disorders, affecting over one billion people globally. Attacks demonstrate rhythmic patterns of onset across the day and seasonally, highlighting that attack onset is influenced by an individual's biological rhythms. Indeed, an individual's chronotype (their endogenous circadian clock rhythm) predicts when they are most likely to have an attack. These biological rhythms are regulated by an endogenous master biological clock in the hypothalamus that coordinates the function of peripheral clocks, aligning biological processes and behaviours to environmental cues (e.g. daily rhythms in light-dark cycles). As such, circadian rhythms are essential to maintain normal neurological function and health, regulating the expression of approximately 50 % of all protein coding genes in mammals. Importantly, the majority of the World Health Organisations essential medicines and several migraine-related therapeutics directly target the products of these rhythmic genes or influence circadian-related genes directly. Therefore, the current review will focus on the potential for chronotherapy in migraine. Highlighting its potential to optimise the chronopharmacokinetic profile, therapeutic efficacy and reduce potential side effects of anti-migraine therapies. A greater understanding of which has the potential for significant impact, representing a low cost, scalable method to improve therapeutic response and inform a personalized therapeutic strategy.

Indexed as

ChronotherapyCircadian RhythmMigraine DisordersAnimalsChronotypeHumansChronotherapyCircadianHeadacheMigraine

Identifiers

PMID41444043
PMCPMC12996776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.